Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000–2014: A Population-based Cohort Study
Authors:
Open Access
- 15 August 2021
- journal article
- research article
- Published by Elsevier in European Urology Open Science
- Vol. 32, 19-27
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Cardiovascular Risk Factors and Disease After Male Germ Cell CancerJournal of Clinical Oncology, 2020
- Predictors of thrombosis in testicular cancer during platinum-based chemotherapyWorld Journal of Urology, 2018
- ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-upAnnals of Oncology, 2018
- Improved survival in metastatic germ-cell cancerAnnals of Oncology, 2017
- Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumoursEuropean Journal of Cancer, 2016
- Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based StudyJournal of Clinical Oncology, 2015
- Large Retroperitoneal Lymphadenopathy As a Predictor of Venous Thromboembolism in Patients With Disseminated Germ Cell Tumors Treated With ChemotherapyJournal of Clinical Oncology, 2015
- Epidemiology of cancer-associated venous thrombosisBlood, 2013
- Myocardial infarction and other major vascular events during chemotherapy for testicular cancerAnnals of Oncology, 2010
- Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapyJournal of Thrombosis and Haemostasis, 2007